Antithrombotic therapy in the prevention of ischemic stroke /

Stroke is the most common cause of adult mortality in the United States. Antithrombotic agents form the mainstay of stroke prevention. Aspirin produces a modest reduction in the risk of second stroke and transient ischemic attack (TIA, mini-stroke) and is widely recommended for initial therapy. The...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Becker, Richard C.
Otros Autores: Spencer, Fredrick A., MD
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Oxford ; New York : Oxford University Press, 2010.
Colección:Oxford American pocket notes.
Temas:
Transient ischemic attack > Chemotherapy.
Transient ischemic attack > Prevention.
Fibrinolytic agents.
Ischemic Attack, Transient > drug therapy
Ischemic Attack, Transient > prevention & control
Fibrinolytic Agents
Accident ischémique transitoire > Chimiothérapie.
Fibrinolytiques.
HEALTH & FITNESS > Diseases > General.
MEDICAL > Clinical Medicine.
MEDICAL > Diseases.
MEDICAL > Evidence-Based Medicine.
MEDICAL > Internal Medicine.
Acceso en línea:Texto completo
Descripción
Sumario:Stroke is the most common cause of adult mortality in the United States. Antithrombotic agents form the mainstay of stroke prevention. Aspirin produces a modest reduction in the risk of second stroke and transient ischemic attack (TIA, mini-stroke) and is widely recommended for initial therapy. The thienopyridines (Ticlid) and clopodogrel (Plavix) are alternatives for secondary prevention in patients who do not respond to or cannot take aspirin. They are no more effective than aspirin and have been associated with thrombotic thrombocytopenic purpura. The combination of aspirin and extended-rel.
Descripción Física:1 online resource (45 pages) : illustrations
Bibliografía:Includes bibliographical references.
ISBN:9780199774449
0199774447

Ejemplares similares